Cost-Utility Analysis Alongside the GORTEC 2014-01 TPExtreme Trial: TPEx Versus EXTREME as First-Line Treatment in Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
Value in Health · 2025
DOI: 10.1016/j.jval.2025.07.032 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Value in Health, 2025. Verfasst von Aldéric M Fraslin und 10 weiteren Autor:innen. Beteiligte Einrichtung: Biostatistics and Epidemiology Unit, Gustave Roussy, Oncostat 1018 INSERM, labeled Ligue Contre le Cancer, University Paris-Saclay, Villejuif, France…. Hauptthemen laut MEDLINE: Squamous Cell Carcinoma of Head and Neck, Antineoplastic Combined Chemotherapy Protocols, Head and Neck Neoplasms, Neoplasm Recurrence, Local. Die Arbeit nennt 23 Literaturangaben. Gefördert von: Merck KGaA, Groupe d'Oncologie Radiothérapie Tête et Cou.
Abstract (Originalsprache)
OBJECTIVES: The randomized GORTEC 2014-01 TPExtreme trial showed no significant improvement in overall survival with TPEx chemotherapy regimen (docetaxel-platinum-cetuximab) versus EXTREME regimen (platinum-fluorouracil-cetuximab) in first-line treatment of recurrent or metastatic head and neck squamous cell carcinoma. However, the TPEx regimen had a favorable safety profile and could provide an alternative to standard of care with the EXTREME regimen in this setting. Our aim was to assess the cost-utility of the TPEx strategy versus EXTREME strategy in the French setting. METHODS: We used a decision-analytic semi-Markov model with 4 health states and 1-month cycles. Resource use was prospectively collected in the GORTEC 2014-01 TPExtreme trial (NCT02268695). Transition probabilities were assessed from patient-level data from the trial (n = 539). In the base-case analysis, direct medical costs from the French National Insurance Scheme and quality-adjusted life-years (QALYs) were computed in both arms over an 18-month time horizon to estimate the incremental net monetary benefit. Deterministic sensitivity analysis and probabilistic sensitivity analysis were conducted. RESULTS: The TPEx regimen was associated with a gain in QALYs (+0.057) and a decrease in cost (-€4 485). In the base-case scenario, the TPEx strategy was dominant over the EXTREME strategy with a positive incremental net monetary benefit amounting to €7349. For a willingness to pay of €50 000 per QALY, the probability of TPEx regimen being cost-effective was 64% and varied between 58% and 67% in the scenario analyses. CONCLUSIONS: The TPEx regimen is likely to be cost-effective compared with EXTREME in the French setting.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Biostatistics and Epidemiology Unit, Gustave Roussy, Oncostat 1018 INSERM, labeled Ligue Contre le Cancer, University Paris-Saclay, Villejuif, France. Electronic address: alderic.fraslin@gustaveroussy.fr.
- Biostatistics and Epidemiology Unit, Gustave Roussy, Oncostat 1018 INSERM, labeled Ligue Contre le Cancer, University Paris-Saclay, Villejuif, France.
- Department of Head and Neck Oncology, Gustave Roussy, Villejuif, France.
- Department of Medical Oncology, University of Lyon, Centre Léon Bérard, Lyon, France.
- Department of Medical Oncology, Centre Antoine Lacassagne, University Côte d'Azur, Nice, France.
- Department of Medical Oncology, ILC Centre Jean Bernard/Clinique Victor Hugo, Le Mans, France.
Förderung
- Merck KGaA
- Groupe d'Oncologie Radiothérapie Tête et Cou
Zitieren
APA
Fraslin, A. M., Aupérin, A., Even, C., Fayette, J., Saada-Bouzid, E., Lafond, C., Geoffrois, L., TPExtreme-ECO Group, Bourhis, J., Guigay, J., & Bonastre, J. (2025). Cost-Utility Analysis Alongside the GORTEC 2014-01 TPExtreme Trial: TPEx Versus EXTREME as First-Line Treatment in Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma. Value in Health. https://doi.org/10.1016/j.jval.2025.07.032
Vancouver
Fraslin AM, Aupérin A, Even C, Fayette J, Saada-Bouzid E, Lafond C, et al. Cost-Utility Analysis Alongside the GORTEC 2014-01 TPExtreme Trial: TPEx Versus EXTREME as First-Line Treatment in Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma. Value in Health. 2025. doi:10.1016/j.jval.2025.07.032
BibTeX
@article{Fraslin2025,
author = {Fraslin, Aldéric M and Aupérin, Anne and Even, Caroline and Fayette, Jérôme and Saada-Bouzid, Esma and Lafond, Cédrik and Geoffrois, Lionnel and TPExtreme-ECO Group, TPExtreme-ECO Group and Bourhis, Jean and Guigay, Joël and Bonastre, Julia},
title = {Cost-Utility Analysis Alongside the GORTEC 2014-01 TPExtreme Trial: TPEx Versus EXTREME as First-Line Treatment in Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma},
journal = {Value in Health},
year = {2025},
doi = {10.1016/j.jval.2025.07.032}
}
EUVIMED